Veeco (VECO) Q2 2026 Earnings Call Transcript

Veeco reported Q2 revenue of $193.5 million (vs. $166.1 million prior year) and non-GAAP diluted EPS of $0.33, exceeding guidance despite the company flagging near-term margin pressure from growth investments. Management secured $200 million of advanced packaging orders for 2027 delivery and raised full-year 2026 revenue guidance to $780–$810 million (from prior expectations), while guiding non-GAAP EPS to $1.36–$1.61; however, gross margin is expected to be pressured by ~75 bps and OpEx up by ~$10 million in 2H26. The company reaffirmed a Q3 revenue range of $200–$220 million and is targeting a 2H26 close for its pending Axcelis merger (subject to China antitrust approval).

Analysis

The key market takeaway is that Veeco is transitioning from a cyclical tool vendor to a quasi-picks-and-shovels beneficiary of AI capex in advanced packaging and silicon photonics. The order backlog and customer deposit build suggest the demand is real enough to justify pre-building capacity, which typically supports a higher forward multiple if investors believe 2027 revenue is now de-risked. The near-term drag is that earnings quality lags revenue quality: margin dilution from capacity expansion can keep the stock from fully reflecting the backlog until shipments inflect.

Second-order winners include downstream AI infrastructure names that need optical interconnects and high-bandwidth memory, while broader semi-equipment peers may be less exposed to this specific mix shift. The larger competitive implication is that Veeco is trying to own the bottleneck steps in newer architectures, which can create stickier share than commodity WFE. That said, this also raises execution risk: if Southeast Asia outsourcing, hiring, or tool qualification slips, the revenue can still show up later than investors expect, and the market will punish any mismatch between bookings and install cadence.

The contrarian view is that the Street may already be extrapolating the 2027 story before it is monetized, while underweighting China regulatory risk and the Axcelis overhang. If China approval drifts, the merger narrative becomes a source of multiple compression rather than upside optionality. The thesis is falsified if backlog fails to convert into sequential shipment acceleration by early 2027, or if gross margin stays structurally below the guided range despite volume leverage.

Key Decisions for Investors

• Long VECO on pullbacks over the next 2-6 weeks; thesis is a 6-12 month rerating as 2027 backlog converts, but cut exposure if 1H27 bookings/shipment cadence slips.
• Pair trade: long VECO / short AMAT or a semi-equipment basket for 3-6 months to isolate exposure to advanced packaging and photonics share gains versus more diversified capex names.
• Use VECO call spreads out 6-9 months if seeking upside to a 2027 ramp without full downside exposure; best if the market keeps discounting near-term margin dilution.
• Watch ACLS as a merger catalyst/overhang, not a standalone long: if China approval is delayed beyond the expected close window, expect spread volatility and multiple compression in both names.